Metrics to compare | 002038 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002038PeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.7x | 31.0x | −0.4x | |
PEG Ratio | 0.03 | −0.84 | 0.00 | |
Price/Book | 1.2x | 2.3x | 2.6x | |
Price / LTM Sales | 10.3x | 5.4x | 3.1x | |
Upside (Analyst Target) | - | 40.2% | 48.8% | |
Fair Value Upside | Unlock | 20.4% | 5.7% | Unlock |
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; dispersible; ornidazole; voriconazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; filgrastim; recombinant human interleukin-11; and recombinant human interleukin-2 products. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People’s Republic of China.